Share on StockTwits

Shares of GlaxoSmithKline plc (LON:GSK) have earned an average recommendation of “Hold” from the twenty-two analysts that are presently covering the company, AnalystRatings.NET reports. Four investment analysts have rated the stock with a sell rating, twelve have assigned a hold rating and six have given a buy rating to the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is GBX 1,634.81 ($27.43).

Several analysts have recently commented on the stock. Analysts at Credit Suisse reiterated an “underperform” rating on shares of GlaxoSmithKline plc in a research note on Friday. They now have a GBX 1,475 ($24.74) price target on the stock. Separately, analysts at Jefferies Group reiterated a “hold” rating on shares of GlaxoSmithKline plc in a research note on Monday, August 11th. They now have a GBX 1,385 ($23.23) price target on the stock. Finally, analysts at Beaufort Securities reiterated a “buy” rating on shares of GlaxoSmithKline plc in a research note on Monday, August 4th.

GlaxoSmithKline plc (LON:GSK) opened at 1392.00 on Wednesday. GlaxoSmithKline plc has a 52-week low of GBX 556.50 and a 52-week high of GBX 2076.00. The stock has a 50-day moving average of GBX 1490.56 and a 200-day moving average of GBX 1585.. The company’s market cap is £66.872 billion.

The company also recently announced a dividend, which is scheduled for Thursday, October 2nd. Stockholders of record on Wednesday, August 6th will be paid a dividend of GBX 19 ($0.32) per share. This represents a dividend yield of 1.28%. The ex-dividend date is Wednesday, August 6th.

GlaxoSmithKline plc (LON:GSK) is global healthcare group, which is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products.

Receive News & Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related companies with Analyst Ratings Network's FREE daily email newsletter.